II

ImageneBio Inc

IMA·NASDAQ

$5.69

+2.3%
HealthcareBiotechnology

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

At a Glance

Live Snapshot
Market Cap$64.18M
EPS-10.7600
P/E Ratio-0.53
Earnings Date07/23/2026

ima

Net Cash Provided by Investing Activities

Last Annual Value

-5.81M

3-Year CAGR

61%

5-Year CAGR

-24%

10-Year CAGR

-4%

II

ImageneBio Inc Competitors Analysis of Net Cash Provided by Investing Activities

IMA · NASDAQ
CompanyNet Cash Provided by Investing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
IMA logo
ImageneBio Inc
NASDAQ:IMA
-5.81M
N/AN/AN/A 
21.91M
N/A-18.0%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
2.39M
N/AN/AN/A
-799.00K
N/AN/AN/A
IMUX logo
Immunic, Inc.
NASDAQ:IMUX
-161.00K
N/AN/AN/A
NTRB logo
Nutriband Inc.
NASDAQ:NTRB
-92.04K
N/AN/AN/A
-12.10M
N/AN/AN/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
16.63M
-27.7%N/AN/A
45.01M
N/AN/A16.7%
-49.85M
N/AN/AN/A
-19.72M
N/AN/AN/A
II

ImageneBio Inc Fair Value Envelope

IMA · NASDAQ

Our analysis suggests that IMA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.69, this represents a potential HIDDEN relative to our calculated worth for ImageneBio Inc.

Intrinsic Value
Current Price: $5.69